Evidence map›Paper›PMID 40018471›Full record

ArticleCureus2025

Long-Term Survival of Metachronous Isolated Adrenal Metastasis in Luminal Breast Cancer: A Case Report and Literature Review.

Griet Verboven, Manon T Huizing, Maarten Weijer, Dirk Ysebaert, Ali Ramadhan, Tim Wyngaert, Glenn Broeckx, Wiebren A Tjalma

Abstract readCase Reports
In one paragraph

Article in Cureus, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.

0numbers the graph read from it
0cells of the map it votes in
0citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

0 citing papers in PubMed.

No citing paper in PubMed yet.

4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

8 authors.

Griet VerbovenFaculty of Medicine and Health Sciences, University of Antwerp, Antwerp, BEL.
Manon T HuizingFaculty of Medicine and Health Sciences, University of Antwerp, Antwerp, BEL.
Maarten WeijerDepartment of Radiology, Antwerp University Hospital, Edegem, BEL.
Dirk YsebaertDepartment of Hepatobiliary, Endocrine and Transplantation Surgery, Antwerp University Hospital, Edegem, BEL.
Ali RamadhanDepartment of Pathology, Antwerp University Hospital, Edegem, BEL.
Tim WyngaertDepartment of Nuclear Medicine, Antwerp University Hospital, Edegem, BEL.
Glenn BroeckxDepartment of Pathology, Gasthuiszusters van Antwerpen (GZA) Ziekenhuis Netwerk Antwerpen (ZNA) Hospitals, Antwerp, BEL.
Wiebren A TjalmaDepartment of Obstetrics and Gynecology, Antwerp University Hospital, Edegem, BEL.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Metachronous metastasis occurs many years later in cases of hormone-positive, human epidermal growth factor receptor 2 (HER2)-negative breast cancer, with the most common sites being the lymph nodes, bones, liver, lungs, and brain. The late recurrence of estrogen receptor (ER)-positive breast cancer is attributed to prolonged adjuvant therapy and the high expression of dormancy-associated genes, allowing cancer cells to survive for decades without proliferating. It is a form of chronic breast cancer that remains asymptomatic, with no clinical signs of progression or recurrence. Estrogen receptor-negative breast cancers, on the other hand, have no long-term tumor dormancy due to their fast growth and low expression of dormancy-related genes. Adrenal gland metastasis, particularly as an oligometastatic presentation, is exceedingly rare, and optimal treatment strategies remain elusive. In this report, we present a case demonstrating long-term survival after treatment of adrenal gland metastasis, accompanied by a comprehensive literature review. At the age of 48, our patient was diagnosed with invasive ductal carcinoma of the left breast. Treatment included breast-conserving surgery, radiotherapy, and adjuvant hormone therapy. Ten years later, she developed a solitary left adrenal metastasis. Treatment included laparoscopic adrenalectomy and a change in hormonal therapy. Our patient is currently still asymptomatic with no evidence of disease. Her overall survival of over 20 years is exceptional. Resection of the adrenal metastasis combined with systemic hormonal therapy represents the recommended approach for this metachronous metastasis. In the contemporary context, antihormonal therapy in combination with CDK4/6 inhibitors should be considered. The present case underscores the necessity of establishing a lifelong (inter)national cancer registry to document rare recurrences systematically. Such a registry would provide insights into the prevalence of uncommon scenarios and offer invaluable data on proposed treatments, facilitating the development of uniform treatment strategies.

Indexed as

breast cancer metastasislong term survivorluminal-like breast cancerminimally invasive adrenalectomyoligo metastatic diseasetumor dormancy

Identifiers

PMID40018471
PMCPMC11867634

What OpenQuestion holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.